Objectives We sought to assess whether serum salusin-β levels are correlated with the presence and severity of coronary artery disease (CAD).
Methods We measured serum salusin-β levels in 278 consecutive patients undergoing coronary angiography (CAG) for the evaluation of CAD and in 126 healthy controls. Serum salusin-β levels were measured by enzyme-linked immunosorbent assay. The severity of CAD was assessed by angiographic coronary atherosclerosis index score system.
Results Serum salusin-β levels were significantly higher in patients undergoing CAG (n = 278) than those in healthy controls (n = 126) (3.81 ± 0.99 vs 4.34 ± 1.40 nmol/L, P < 0.01). In patients undergoing CAG, patients with CAD (n = 160) had significantly higher serum salusin-β levels compared to patients without CAD (n = 118) (4.65 ± 1.44 vs 3.94 ± 1.23 nmol/L, P < 0.01). Multivariate logistic regression analysis revealed that serum salusin-β levels were independently associated with the presence of CAD (odds ratio, 1.439; 95% confidence interval, 1.176–1.760; P < 0.01). Serum salusin-β levels were positively correlated with the coronary atherosclerosis index score (r = 0.316, P < 0.001).
Conclusions Serum salusin-β levels were associated with the presence and severity of CAD. Salusin-β in serum might serve as a potential biomarker for reflecting the development and progression of CAD. Therapeutic treatment by inhibiting salusin-β interaction to prevent CAD warrants further investigation.
- coronary artery disease
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.